Expert Insight Into:
Survival Among Women with Triple Receptor-Negative Breast Cancer and Brain Metastases
Medical Writer: Nicole M. Avena, PhD
Expert Faculty: Ana Maria Gonzalez-Angulo, MD, MSc, FACP
Medical Writer: Nicole M. Avena, PhD
Expert Faculty: Ana Maria Gonzalez-Angulo, MD, MSc, FACP
Click here to view our current activities in Oncology.
Survival outcomes and incidence of developing brain metastases have been inferred for patients with nonmetastatic triple receptor-negative breast cancer, but not directly measured. Dr. Ana Maria Gonzalez-Angulo describes a study on the incidence of brain metastases and survival in women originally diagnosed with triple-negative, nonmetastatic breast cancer.
Ana Maria Gonzalez-Angulo, MD, MSc, FACP
- Assistant Professor
- Breast Medical Oncology
- The University of Texas MD Anderson Cancer Center
- Houston, TX
Maura N. Dickler, MD, has received honoraria from Hoffmann-La Roche Inc; and is on the advisory boards of AstraZeneca, Genentech Inc, GlaxoSmithKline, Novartis Pharmaceuticals, and Pfizer Inc.
Ana Maria Gonzalez-Angulo, MD, MSc, FACP, has received grant/research support from Abraxis BioScience, Bristol-Myers Squibb, Genomic Health, Merck & Company, Novartis Pharmaceuticals, and Roche Diagnostics.
William J. Gradishar, MD, FACP, has no significant relationships to disclose.
Ian E. Smith, MD, FRCP, FRCPE, has received honoraria from Hoffmann-La Roche Inc; and is on the advisory board of Genentech Inc.
Available for CME/CE:
Physicians
Publish Date: Oct 28, 2009 Termination Date: Oct 28, 2010Nurses
Publish Date: Oct 28, 2009 Termination Date: Oct 28, 2010Pharmacists
Publish Date: Oct 28, 2009 Termination Date: Oct 28, 2010Estimated time for completion of this activity:
CNE: 33.00 minutes
CPE: 45.00 minutes
Target Audience
This activity is designed for medical oncologists and other clinicians involved in the care of patients with breast cancer.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for diagnosing, treating, and managing patients with breast cancer.
Learning Objective (s)
- Evaluate the data on OS, RFS, and the incidence of brain metastases from a retrospective study of patients with triple receptor-negative, nonmetastatic breast cancer to inform treatment options.
- Analyze data on the occurrence of brain metastases from a retrospective study of patients with triple receptor-negative breast cancer, and apply this knowledge to the treatment of patients in this cohort.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 0.55 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
You must complete two article reviews to receive a certificate of 1 or more contact hours. Your statement of credit will be available once you have completed the posttest and evaluation associated with each article review. Projects In Knowledge will record your participation in each article review in your CE tracker.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-09-089-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Ana Maria Gonzalez-Angulo, MD, MSc, FACP has received grant/research support from Abraxis BioScience, Bristol-Myers Squibb, Genomic Health, Merck & Company, Novartis Pharmaceuticals, and Roche Diagnostics.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nicole M. Avena, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Harold J. Burstein, MD, PhD has no significant relationships to disclose.
Maura N. Dickler, MD has received honoraria from Hoffmann-La Roche Inc; and is on the advisory boards of AstraZeneca, Genentech Inc, GlaxoSmithKline, Novartis Pharmaceuticals, and Pfizer Inc.
Ana Maria Gonzalez-Angulo, MD, MSc, FACP has received grant/research support from Abraxis BioScience, Bristol-Myers Squibb, Genomic Health, Merck & Company, Novartis Pharmaceuticals, and Roche Diagnostics.
William J. Gradishar, MD, FACP has no significant relationships to disclose.
Ian E. Smith, MD, FRCP, FRCPE has received honoraria from Hoffmann-La Roche Inc; and is on the advisory board of Genentech Inc.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Oct 28, 2009 Termination Date: Oct 28, 2010Nurses
Publish Date: Oct 28, 2009 Termination Date: Oct 28, 2010Pharmacists
Publish Date: Oct 28, 2009 Termination Date: Oct 28, 2010Estimated time for completion of this activity:
CNE: 33.00 minutes
CPE: 45.00 minutes
Target Audience
This activity is designed for medical oncologists and other clinicians involved in the care of patients with breast cancer.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for diagnosing, treating, and managing patients with breast cancer.
Learning Objective (s)
- Evaluate the data on OS, RFS, and the incidence of brain metastases from a retrospective study of patients with triple receptor-negative, nonmetastatic breast cancer to inform treatment options.
- Analyze data on the occurrence of brain metastases from a retrospective study of patients with triple receptor-negative breast cancer, and apply this knowledge to the treatment of patients in this cohort.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 0.55 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
You must complete two article reviews to receive a certificate of 1 or more contact hours. Your statement of credit will be available once you have completed the posttest and evaluation associated with each article review. Projects In Knowledge will record your participation in each article review in your CE tracker.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-09-089-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Ana Maria Gonzalez-Angulo, MD, MSc, FACP has received grant/research support from Abraxis BioScience, Bristol-Myers Squibb, Genomic Health, Merck & Company, Novartis Pharmaceuticals, and Roche Diagnostics.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nicole M. Avena, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Harold J. Burstein, MD, PhD has no significant relationships to disclose.
Maura N. Dickler, MD has received honoraria from Hoffmann-La Roche Inc; and is on the advisory boards of AstraZeneca, Genentech Inc, GlaxoSmithKline, Novartis Pharmaceuticals, and Pfizer Inc.
Ana Maria Gonzalez-Angulo, MD, MSc, FACP has received grant/research support from Abraxis BioScience, Bristol-Myers Squibb, Genomic Health, Merck & Company, Novartis Pharmaceuticals, and Roche Diagnostics.
William J. Gradishar, MD, FACP has no significant relationships to disclose.
Ian E. Smith, MD, FRCP, FRCPE has received honoraria from Hoffmann-La Roche Inc; and is on the advisory board of Genentech Inc.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



